<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347947">
  <stage>Registered</stage>
  <submitdate>14/02/2012</submitdate>
  <approvaldate>24/05/2012</approvaldate>
  <actrnumber>ACTRN12612000554864</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and acceptability of needles 4 mm length in pediatric insulin therapy</studytitle>
    <scientifictitle>Pediatric patients affected by type 1 diabetes teaching to use 4 mm length needles for insulin therapy compared with diabetic children using 8 mm length needles regarding metabolic control parameters and quality of life</scientifictitle>
    <utrn>U1111-1127-1444</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>type 1 diabetes</healthcondition>
    <healthcondition>risk of intramuscolar insulin injection</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Use of 4 mm length needles for insulin administration for a period of 12 months, in newly type1 diabetic children or shift to 4 mm needles in patients undergoing therapy by 8 mm length needles; because the dosage of insulin should be adjusted according to blood glucose values, all patients are required to perform blood glucose testing at least 4 times/day and to apply a provided therapy algorithm
All patients and their parents will undergoing a 30 minutes instruction course, carried out by a trained nurse specialist, around  the self-administration of insulin (if &gt; 10 years old) or administration by parents (if &lt; 10 years old), specifically aimed to the use of the needle of 4mm length</interventions>
    <comparator>Use of 8 mm length needles for insulin administration</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>average HbA1c from baseline, assessed by Siemens DCA Vantage Analizer</outcome>
      <timepoint>3,6,9, 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin/weight ratio, assessed on quarterly basis results of clinical examination and daily insulin requirements from glycemic diary</outcome>
      <timepoint>3, 6, 9, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glycemic variability assessed by HBGI and LBGI evaluation of glucometer downloaded data (Accuchek SmartPix )</outcome>
      <timepoint>6, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life, assessed by  Happy Face Rating Scale and Tuula-Maria Partanen questionnaire (Pract Diab Int april 2002 Vol. 19 No. 3)</outcome>
      <timepoint>6, 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>type 1 diabetes</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>coeliac disease, thyroiditis, psichiatryc impairment, coagulation disease; HbA1c &gt; 9,5% (except time of diagnosis)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Therapy by 4 mm needles will be proposed to every newly diagnosed type 1 diabetes children treated at our regional centre and to all patients previously using 8 mm needles at periodic control time</concealment>
    <sequence>na</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Tuscany</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>AOU Meyer Children Hospital</primarysponsorname>
    <primarysponsoraddress>Viale Pieraccini 24 50139 Florence</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Availability of new, short length, 4 mm needles for insulin therapy could improve compliance in children with type 1 diabetes; however, there are some concerns about insulin leakage and efficacy of these devices.
We aim to test efficacy and assess satisfation of 4 mm length needles use in a population of children with newly diagnosed type 1 diabetes or previously undergoing insulin therapy four-time a day by 8-mm length needles</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Meyer's Ethics Committee</ethicname>
      <ethicaddress>Meyer Children Hospital, Viale Pieraccini 24 50139 Florence</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lenzi Lorenzo</name>
      <address>Meyer Children Hospital, Viale Pieraccini 24, 50139 Florence</address>
      <phone>+39 055 5662570</phone>
      <fax>+39 055 5662486</fax>
      <email>lr.lenzi@meyer.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lenzi Lorenzo</name>
      <address>Meyer Children Hospital, Viale Pieraccini 24, 50139 Florence</address>
      <phone>+39 055 5662570</phone>
      <fax>+39 055 5662486</fax>
      <email>lr.lenzi@meyer.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lenzi Lorenzo</name>
      <address>Meyer Children Hospital, Viale Pieraccini 24, 50139 Florence</address>
      <phone>+39 055 5662570</phone>
      <fax>+39 055 5662486</fax>
      <email>lr.lenzi@meyer.it</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>